Vanguard Capital Management
AVBP icon

Vanguard Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Vanguard Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.7M Buy
1,774,873
+245,980
+16% +$7.26M ﹤0.01% 1821
2026
Q1 		$35.3M Buy
+1,528,893
New +$34.5M ﹤0.01% 2045

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management's AVBP Position: Q2 2026 in Review

Vanguard Capital Management increased its ArriVent BioPharma (AVBP) stake by 16% in Q2 2026, buying an estimated $7.26M and bringing the position to 1,774,873 shares worth $61.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1821.

Vanguard Capital Management first reported a position in AVBP in Q1 2026 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Vanguard Capital Management held 1,774,873 shares of ArriVent BioPharma worth $61.7M as of Q2 2026.
  • Vanguard Capital Management bought 245,980 ArriVent BioPharma shares in Q2 2026, an estimated $7.26M.
  • ArriVent BioPharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1821 holding.
  • Vanguard Capital Management first reported a position in ArriVent BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.